Intestine-Targeted DGAT1 Inhibition Improves Obesity and Insulin Resistance without Skin Aberrations in Mice

• Naoto Tsuda ,

  * E-mail: naoto.tsuda@mochida.co.jp

  Affiliations Discovery Research, Mochida Pharmaceutical Company Limited, Shizuoka, Japan, Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

  ⨯
• Shin Kumadaki,

  Affiliation Discovery Research, Mochida Pharmaceutical Company Limited, Shizuoka, Japan

  ⨯
• Chika Higashi,

  Affiliation Discovery Research, Mochida Pharmaceutical Company Limited, Shizuoka, Japan

  ⨯
• Makoto Ozawa,

  Affiliation Discovery Research, Mochida Pharmaceutical Company Limited, Shizuoka, Japan

  ⨯
• Mikihiko Shinozaki,

  Affiliation Discovery Research, Mochida Pharmaceutical Company Limited, Shizuoka, Japan

  ⨯
• Yutaka Kato,

  Affiliation Discovery Research, Mochida Pharmaceutical Company Limited, Shizuoka, Japan

  ⨯
• Koutarou Hoshida,

  Affiliation Discovery Research, Mochida Pharmaceutical Company Limited, Shizuoka, Japan

  ⨯
• Satomi Kikuchi,

  Affiliation Discovery Research, Mochida Pharmaceutical Company Limited, Shizuoka, Japan

  ⨯
• Yoshihisa Nakano,

  Affiliation Discovery Research, Mochida Pharmaceutical Company Limited, Shizuoka, Japan

  ⨯
• Yoshihiro Ogawa,

  Affiliation Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

  ⨯
• Shoji Furusako

  Affiliation Discovery Research, Mochida Pharmaceutical Company Limited, Shizuoka, Japan

  ⨯